Table 2. Perinatal baseline characteristics and outcomes of discharged infants with GA ≤ 32 weeks.
| Characteristics | GA 22–24 weeks (n = 87) |
GA 25–26 weeks (n = 434) |
GA 27–28 weeks (n = 968) |
Subtotal GA≤28 weeks (n = 1489) | GA 29–30 weeks (n = 1454) |
GA 31–32 weeks (n = 1906) |
GA Total ≤ 32 weeks (n = 4849) |
|---|---|---|---|---|---|---|---|
| Antenatal steroid, two doses, n (%) | 34 (39.1%) | 182 (41.9%) | 398 (41.1%) | 614 (41.2%) | 580 (39.9%) | 738 (38.7%) | 1932 (39.8%) |
| Preeclampsia, n (%) | 9 (10.3%) | 76 (17.5%) | 220 (22.7%) | 305 (20.5%) | 332 (22.8%) | 399 (20.9%) | 1036 (21.4%) |
| Gestational diabetes, n (%) | 2 (2.3%) | 22 (5.1%) | 63 (6.5%) | 87 (5.8%) | 88 (6%) | 137 (7.2%) | 312 (6.4%) |
| Chorioamnionitis, n (%) | 15 (17.2%) | 65 (15%) | 128 (13.2%) | 208 (14%) | 133 (9.1%) | 140 (7.3%) | 481 (10%) |
| IVF pregnancy, n (%) | 17 (19.5%) | 36 (8.3%) | 106 (11%) | 159 (10.7%) | 154 (10.6%) | 215 (11.3%) | 528 (10.9%) |
| Multiple births | |||||||
| Twin, n (%) | 20 (23%) | 60 (13.8%) | 202 (20.9%) | 282 (18.9%) | 316 (21.7%) | 550 (28.8%) | 1148 (23.7%) |
| Triplet, n (%) | 1(1.1%) | 15 (3.4%) | 34 (3.5%) | 50 (3.3%) | 64 (4.4%) | 94 (4.9%) | 208 (4.3%) |
| Vaginal delivery, n (%) | 23 (26.4%) | 96 (22.1%) | 157 (16.2%) | 276 (18.5%) | 226 (15.5%) | 271 (14.2%) | 773 (15.9%) |
| Gestational age (weeks)* | 23.5±0.6 | 25.6±0.4 | 27.6±0.5 | 26.8±1.3 | 29.6±0.5 | 31.5±0.5 | 29.5±2.1 |
| Birth weight, (grams)* | 683±123 | 853±163 | 1078 ± 223 | 987±241 | 1345 ± 281 | 1626 ± 329 | 1345 ± 392 |
| Male gender, n (%) | 43 (49.4%) | 213 (49.1%) | 497 (51.3%) | 753 (50.6%) | 787 (54.1%) | 971 (50.9%) | 2511 (51.8%) |
| SGA, n (%) | 6 (6.9%) | 108 (24.9%) | 184 (19%) | 298 (20%) | 232 (15.9%) | 222 (11.6%) | 752 (15.5%) |
| Resuscitation at birth, n (%) | 84 (96.5%) | 329 (75.8%) | 606 (62.6%) | 1019 (68.4%) | 651 (44.8%) | 645 (33.8%) | 2315 (47.7%) |
| RDS, n (%) | 87 (100%) | 397 (91.5%) | 811 (83.8%) | 1295 (87%) | 969 (66.6%) | 935 (49%) | 3199 (66%) |
| Surfactant treatment, n (%) | 85 (97.7%) | 373 (85.9%) | 715 (73.9%) | 1173 (78.8%) | 745 (51.2%) | 651 (34.1%) | 2569 (53%) |
| Duration of invasive mechanical ventilation (days)** | 40 (13–56) | 10 (1–30) | 2 (0–9) | 4 (0–18) | 0 (0–3) | 0 (0–1) | 0(0–4) |
| Duration of noninvasive ventilation (days)** | 22(10–31) | 17(7–30) | 8(4–18) | 11 (4–35) | 4 (2–8) | 2 (1–5) | 4 (2–10) |
| Total days on oxygen (days)** | 80 (57–114) | 60(38–84) | 33 (12–52) | 42(19–66) | 11 (5–27) | 6 (2–12) | 12 (5–35) |
| PDA requiring treatment, n (%) | 60 (69%) | 216 (49.8%) | 320 (33%) | 596 (40%) | 233 (16%) | 152 (8%) | 981 (20.2%) |
| Intracranial hemorrhage (> Grade II), n (%) |
15 (17.2%) | 56 (12.9%) | 66 (6.8%) | 137 (9.2%) | 49 (3.4%) | 41 (2.1%) | 227 (4.7%) |
| Late-onset sepsis, n (%) | 75 (86.2%) | 304 (70%) | 474 (49%) | 853 (57.3%) | 508 (34.9%) | 433 (22.7%) | 1794 (37%) |
| Culture proven, n (%) | 37 (42.5%) | 154 (35.5%) | 245 (25.3%) | 436 (29.3%) | 237 (16.3%) | 209 (11%) | 882 (18.2%) |
| NEC (≥ Stage II), n (%) | 22 (25.3%) | 68 (15.7%) | 117 (12.1%) | 207 (13.9%) | 109 (7.5%) | 92 (4.8%) | 408 (8.4%) |
| BPD, n (%) | 65 (74.7%) | 239 (55.1%) | 295 (30.5%) | 599 (40.2%) | 208 (14.3%) | 121 (6.3%) | 928 (19.1%) |
| Any degree of ROP, n (%) | 68 (78.2%) | 350 (80.6%) | 526 (54.3%) | 944 (63.4%) | 422 (29%) | 230 (12.1%) | 1596 (32.9%) |
| Severe ROP, n (%) | 49 (56.3%) | 151 (34.8%) | 120 (12.4%) | 320 (21.5%) | 58 (4%) | 18 (0.9%) | 396 (8.2%) |
GA: Gestational age, IVF: Invitro fertilization, SGA:Small for gestational age, RDS:Respiratory distress syndrome, PDA: Patent ductus arteriosus, NEC:Necrotizing enterocolitis, BPD:Bronchopulmonary dysplasia, ROP: Retinopathy of prematurity
*Values are presented as mean±standart deviation
** Values are presented as median, and IQR (interquartile range) are given in parenthesis